These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33234004)

  • 1. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition.
    Musunuru K
    Annu Rev Med; 2021 Jan; 72():447-458. PubMed ID: 33234004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
    Lee S; Cannon CP
    Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of lipid management in acute coronary syndrome.
    Fujisue K; Tsujita K
    J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy.
    Rallidis LS; Triantafyllis AS; Iliodromitis E
    Hellenic J Cardiol; 2018; 59(5):293-295. PubMed ID: 29128548
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
    Leong D; Wu PE
    CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
    [No Abstract]   [Full Text] [Related]  

  • 12. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical guide for the use of PCSK9 inhibitors in Portugal.
    Fontes-Carvalho R; Marques Silva P; Rodrigues E; Araújo F; Gavina C; Ferreira J; Morais J
    Rev Port Cardiol (Engl Ed); 2019 Jun; 38(6):391-405. PubMed ID: 31324407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy.
    Kuyama N; Kataoka Y; Takegami M; Nishimura K; Harada-Shiba M; Hori M; Ogura M; Otsuka F; Asaumi Y; Noguchi T; Tsujita K; Yasuda S
    J Am Heart Assoc; 2021 Jun; 10(11):e019525. PubMed ID: 33998287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
    Oren O; Kludtke EL; Kopecky SL
    Am J Cardiol; 2019 Dec; 124(11):1669-1673. PubMed ID: 31740018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
    Ingueneau C; Hollstein T; Grenkowitz T; Ruidavets JB; Kassner U; Duparc T; Combes G; Perret B; Genoux A; Schumann F; Bobbert T; Steinhagen-Thiessen E; Martinez LO
    Vascul Pharmacol; 2020 Dec; 135():106804. PubMed ID: 32987194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.